BEAM Historical PE Ratio Notes

— Beam Therapeutics (ticker symbol BEAM) is a biotechnology company focused on pioneering precision genetic medicines through base editing—a next-generation CRISPR technology allowing targeted, single-base changes in DNA to potentially correct genetic diseases at their source. BEAM's platform is designed to develop therapies for serious conditions, including rare genetic disorders of the liver, blood, and eye, as well as certain cancers. As you explore BEAM's historical PE ratio charts & tables, it is crucial to understand that, like many innovative biotech firms, Beam has not yet reached consistent profitability; rather, the company is in an intensive research & development phase. Because of this, historical PE ratios for BEAM may be extremely high, undefined, or negative when the company reports losses (since negative earnings make traditional PE ratios mathematically inapplicable). Stock market participants often assign speculative value to BEAM based on future growth potential rather than current profits, leading to historical valuation metrics that may not align with those of established, profitable companies. When examining BEAM's historical PE ratios, keep in mind that such ratios may reflect investor optimism regarding breakthrough treatments rather than a reflection of underlying earnings strength.

On this page we presented the BEAM Historical PE Ratio information for Beam Therapeutics' stock. The average BEAM historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 24.0. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average BEAM historical PE based on this TTM earnings result method is 26.1. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this BEAM historical PE result, against the recent PE: when this page was posted on 8/11/2026, the most recent closing price for BEAM had been 26.85, and the most recent quarterly earnings result, annualized, was 6.92. Meanwhile, the most recent TTM earnings summed to 0.97. From these numbers, we calculate the recent BEAM PE on 8/11/2026 based on annualized quarterly EPS was 3.9. Based on BEAM's history, that recent PE is low relative to the historical average, with the recent PE 83.8% lower than the historical average PE across our data set for Beam Therapeutics. Looking at the recent BEAM PE on 8/11/2026 based on TTM EPS, we calculate the ratio at 27.7. Based on BEAM's history, that recent PE is elevated relative to the historical average, with the recent PE 6.1% higher than the historical average PE across our Beam Therapeutics data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on BEAM or any other given stock, valuation analysis for BEAM can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Beam Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for BEAM. Thanks for visiting, and the next time you need to research BEAM Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.